

DOSES OF IBD THERAPIES IN ADULTS

	Induction	Maintenance
Oral mesalazine	≥2 g/d- 4.8g/d	≥2 g/d
Topical mesalazine	≥1 g/d	≥1 g/d
Azathioprine	Thiopurines are not used for induction of remission	1.5-2.5 mg/kg/d*
Mercaptopurine		0.75-1.5 mg/kg/d*
Methotrexate	25 mg IM/week Rarely used for induction alone	15 mg IM/week
Infliximab	IV 5 mg/kg (0,2,6w)	5 mg/kg q8w
	IV 5 mg/kg (0,2 w)	SC 120 mg q2w
Adalimumab	SC 160/80/40 mg (0,2,4 w)	40 mg q2w
Golimumab	SC 200/ 100 mg (0,2 w)	If weight: < 80kg: 50mg q4w >80kg: 100 mg q4w
Certolizumab	SC 400 mg (0,2,6 w)	400 mg q4w
Vedolizumab	IV 300 mg (0,2,6w)	300 mg q8w
	IV 300 mg (0,2 w)	SC 108 mg q2w
Ustekinumab	IV 1st dose If weight: < 55kg: 260 mg 55-85kg: 390 mg >85 kg: 520 mg	SC 90 mg q8w/q12w
Risankizumab	IV CD: 600 mg (0,4,8 w) UC: 1200mg (0,4,8w)	SC 4th dose w12 & q8w 360 mg or 180 mg
Mirikizumab	IV UC:300 mg (0,4,8 w) CD: 900mg (0,4,8w)	SC UC: 200 mg q4w CD: 300mg q4w
Guselkumab	IV UC& CD: 200 mg (0,4,8 w)	SC w12 200mg & q4w w16 100mg & q8w
	SC UC& CD: 400 mg (0,4,8 w)	
Tofacitinib	10mg BD	5mg BD
Filgotinib	200 mg/d	200 mg/d
Upadacitinib	45 mg/d for 8w in UC 45 mg/d for 12w in CD	15-30 mg/d
Ozanimod	Days 1-4: 0.23 mg Days 5-7: 0.46 mg Thereafter: 0.92 mg	0.92 mg/day
Etrasimod	2 mg/day	2 mg/day

*Dose adjustment required for patients on allopurinol or with low or intermediate TPMT activity
NOTE: only standard doses were provided. Some biological drugs can be intensified

Gros B, Kaplan G. JAMA. 2023;330(10):951-965
ECCO, BSG, AGA, ACG guidelines

Gros B www.ibd-eii.com

